Metastatic Renal Cell Carcinoma Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Metastatic Renal Cell Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Metastatic Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Metastatic Renal Cell Carcinoma Pipeline Report
• Over 40+ Metastatic Renal Cell Carcinoma companies are evaluating 50+ Metastatic Renal Cell Carcinoma pipeline therapies in various stages of development, and their anticipated acceptance in the Metastatic Renal Cell Carcinoma market would significantly increase market revenue.
• The leading Metastatic Renal Cell Carcinoma Companies working in the market include AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4 Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd., Betta Pharmaceuticals, Exelixis, Hutchison Medipharma Limited, Sumitomo Pharma, NGM Biopharmaceuticals, Ocellaris Pharma, Oncorena AB, and others.
• Promising Metastatic Renal Cell Carcinoma Pipeline Therapies to include Olaparib, Atezolizumab, TP-1454, ALLO 316, SO-C101, VB10.NEO, PF-07209960, INCB001158, IPI-549, DSP-7888, Belzutifan, CD70 CAR-T, Sitravatinib, Pexastimogene Devacirepvec, Gevokizumab, AK104, CCT301-38, Pamiparib, ONC-392, Batiraxcept, AZD6738, NBTXR3, NKT2152, Bempegaldesleukin, Abemaciclib, Abexinostat, CM082, Savolitinib, Epacadostat, MEDI4736, XL092, Fruquintinib, DSP-7888, NGM 707, OC-001, Orellanine, and others.
• April 2024: Ipsen announced a study of Phase 2 clinical trials for Cabozantinib. The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted therapy.
• April 2024: Ontario Clinical Oncology Group (OCOG) announced a study of Phase 2 clinical trials for Ipilimumab/ Nivolumab. This trial will evaluate the addition of cytoreductive stereotactic body radiation therapy (SBRT) to standard of care combination ipilimumab and nivolumab (I/N) versus I/N alone for the treatment of metastatic kidney cancer.

To explore more information on the latest breakthroughs in the Metastatic Renal Cell Carcinoma Pipeline treatment landscape of the report, click here @ Metastatic Renal Cell Carcinoma Pipeline Outlook

In the Metastatic Renal Cell Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Metastatic Renal Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Metastatic Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Metastatic Renal Cell Carcinoma Overview
Renal cell carcinoma is the most common type of kidney cancer in adults. It accounts for approximately 85% of neoplasms arising from the kidney. Renal cell carcinoma may remain clinically occult for most of its course. Only 10% of patients present with the classic triad of flank pain, hematuria, and flank mass. Patients with renal cell cancer (RCC) develop metastatic spread in approximately 33% of cases. The clinical management of patients with metastatic RCC is complicated by the lack of significant efficacy from available therapies.

Find out more about Metastatic Renal Cell Carcinoma Therapeutics Assessment @ Metastatic Renal Cell Carcinoma Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Metastatic Renal Cell Carcinoma Emerging Drugs Profile

• Olaparib: AstraZeneca
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2. PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer. It was first approved by the FDA and EU in December 2014. Currently, it is in Phase II stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma.

• Atezolizumab: Genentech
Atezolizumab is a humanized IgG antibody that binds PD-L1, preventing its interaction with PD-1 and B7-1. Preventing the interaction of PD-L1 and PD-1 removes inhibition of immune responses such as the anti-tumor immune response but not antibody dependent cellular cytotoxicity. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum based chemotherapy, or whose tumors do not respond to platinum based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. Currently, it is in Phase III stage of clinical trial evaluation to treat metastatic Renal Cell Carcinoma.

• TP-1454: Sumitomo Dainippon Pharma
TP-1454 is an investigational oral pyruvate kinase M2 isoform (PKM2) activator,that is currently being evaluated in a Phase 1/1b study in patients with advanced metastatic or progressive solid tumors (NCT04328740). TP-1454 is the first PKM2 activator to be evaluated in cancer patients. Pyruvate kinase is the enzyme responsible for catalyzing the last step of glycolysis. PKM2 plays a critical role in the metabolic changes observed in cancer and immune cells and establishes a metabolic advantage for tumor cells over the tumor immune microenvironment.

Metastatic Renal Cell Carcinoma Therapeutics Assessment
There are approx. 40+ key Metastatic Renal Cell Carcinoma companies which are developing the Metastatic Renal Cell Carcinoma therapies. The Metastatic Renal Cell Carcinoma companies which have their Metastatic Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Genentech.

DelveInsight's Metastatic Renal Cell Carcinoma pipeline report covers around 50+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Metastatic Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Metastatic Renal Cell Carcinoma Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Learn more about the emerging Metastatic Renal Cell Carcinoma Pipeline Therapies @ Metastatic Renal Cell Carcinoma Clinical Trials Assessment- https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Metastatic Renal Cell Carcinoma Pipeline Report
• Coverage- Global
• Metastatic Renal Cell Carcinoma Companies- AstraZeneca, Genentech, Sumitomo Dainippon Pharma, Allogene Therapeutics, Nektar Therapeutics, Eli Lilly and Company, Xynomic Pharmaceuticals, AnewPharma, HUTCHMED, MedImmune, Incyte Corporation, NiKang Therapeutics, OncoC4 Inc., Nanobiotix, Aravive, Mirati Therapeutics Inc., BeiGene, Shanghai PerHum Therapeutics Co., Ltd., Akeso Biopharma, Novartis Pharmaceuticals, Vaccibody, SillaJen, Inc., Chongqing Precision Biotech Co., Ltd, Infinity Pharmaceuticals, Inc., SOTIO Biotech AG, Pfizer, Peloton Therapeutics, Inc., NeoTX Therapeutics Ltd., Betta Pharmaceuticals, Exelixis, Hutchison Medipharma Limited, Sumitomo Pharma, NGM Biopharmaceuticals, Ocellaris Pharma, Oncorena AB, and others.
• Metastatic Renal Cell Carcinoma Pipeline Therapies- include Olaparib, Atezolizumab, TP-1454, ALLO 316, SO-C101, VB10.NEO, PF-07209960, INCB001158, IPI-549, DSP-7888, Belzutifan, CD70 CAR-T, Sitravatinib, Pexastimogene Devacirepvec, Gevokizumab, AK104, CCT301-38, Pamiparib, ONC-392, Batiraxcept, AZD6738, NBTXR3, NKT2152, Bempegaldesleukin, Abemaciclib, Abexinostat, CM082, Savolitinib, Epacadostat, MEDI4736, XL092, Fruquintinib, DSP-7888, NGM 707, OC-001, Orellanine, and others.
• Metastatic Renal Cell Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

Dive deep into rich insights for drugs for Metastatic Renal Cell Carcinoma Market Drivers and Metastatic Renal Cell Carcinoma Market Barriers, click here @ Metastatic Renal Cell Carcinoma Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Metastatic Renal Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Renal Cell Carcinoma - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Atezolizumab: Genentech
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Olaparib: AstraZeneca
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. TP-1454: Sumitomo Dainippon Pharma
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Renal Cell Carcinoma Key Companies
21. Metastatic Renal Cell Carcinoma Key Products
22. Metastatic Renal Cell Carcinoma- Unmet Needs
23. Metastatic Renal Cell Carcinoma- Market Drivers and Barriers
24. Metastatic Renal Cell Carcinoma- Future Perspectives and Conclusion
25. Metastatic Renal Cell Carcinoma Analyst Views
26. Metastatic Renal Cell Carcinoma Key Companies
27. Appendix

Got Queries? Find out the related information on Metastatic Renal Cell Carcinoma Mergers and acquisitions, Metastatic Renal Cell Carcinoma Licensing Activities @ Metastatic Renal Cell Carcinoma Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/metastatic-renal-cell-carcinoma-mrcc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.